Which of the following antidepressants is commonly used to treat atypical depression?

Atypical depression is characterized by specific symptoms such as mood reactivity, increased appetite, significant weight gain, and hypersomnia. Among the treatment options available, monoamine oxidase inhibitors (MAOIs) have shown particular efficacy for atypical depression.

MAOIs work by increasing levels of neurotransmitters such as serotonin and norepinephrine in the brain, which can alleviate the symptoms of atypical depression. They are often used when other antidepressants have not provided sufficient relief, especially due to their unique action on neurotransmitter metabolism.

While other classes of antidepressants, such as SSRIs, tricyclic antidepressants (TCAs), and norepinephrine and specific serotonergic antidepressants (NaSSAs), can be effective for general depression, MAOIs are specifically noted for their effectiveness in addressing the unique symptoms of atypical depression, giving them a specific place in the treatment protocol for this condition. Thus, they are the preferred choice for treating atypical depression due to their targeted action and historical effectiveness in clinical settings.